Structured Abstract
Objective To track uptake of workplace SARS-CoV-2 testing programs using publicly-available data (e.g., press releases), supplementing findings from employer surveys.
Methods We tracked testing programs reported by 1,159 Canadian and 1,081 international employers across sectors from March 1, 2020 to March 31, 2021. We analyzed trends in uptake of testing programs, including over time and by workplace setting.
Results 9.5% (n=110) of Canadian employers and 24.6% (n=266) of international employers tracked reported testing. The prevalence of reported testing programs was less than 20% in some settings associated with high risk of transmission including retail and customer-facing environments, and indoor and mixed blue collar workplaces.
Conclusions Publicly-available data suggest that fewer employers are testing than indicated by surveys. Workplace safety in high-risk workplaces could be further improved by implementing testing strategies that deploy both screening and diagnostic tests.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Public Health Agency of Canada through Canada's COVID-19 Immunity Task Force.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
REB approval and waiver was not necessary as this was a secondary analysis of publicly-available data; no patient or individual-level data was involved.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Sources: Canada’s COVID-19 Immunity Task Force, through the Public Health Agency of Canada.
Conflict of Interest: TW reports personal fees from AbbVie outside this work. RKA reports grants from the Canadian Medical Association Joule Innovation Fund and the World Health Organization Health Emergencies Programme outside this work.
Address for Reprints: Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, Canada, T2N 4N1.
Ethical Considerations & Disclosure(s): None declared.
Data Availability
The data that support the findings of this study are available from the corresponding author, ND, upon reasonable request.